Stavros G. Vizirgianakis - Oct 29, 2021 Form 4 Insider Report for Bioventus Inc. (BVS)

Role
Director
Signature
/s/ Anthony D'Adamio, Attorney-in-Fact
Stock symbol
BVS
Transactions as of
Oct 29, 2021
Transactions value $
$0
Form type
4
Date filed
4/28/2022, 04:24 PM
Previous filing
Jul 2, 2021
Next filing
Jun 22, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BVS Class A Common Stock Award +2.78M 2.78M Oct 29, 2021 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the Agreement and Plan of Merger, dated as of July 29, 2021 (the "Merger Agreement"), each share of Misonix Inc. ("Misonix") common stock (a "Misonix Option") that was outstanding immediately prior to the effective time of the transactions contemplated by the Merger Agreement (the "Effective Time"), was converted into the right to receive a per share amount (the "Merger Consideration") equal to either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and non-assessable shares of the Company's Class A Common Stock, $0.001 par value per share ("Bioventus Shares"). The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder.